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Several homeopathic remedies, namely, Pulsatilla Nigricans (30th potency), Ceanothus
Americanus (both mother tincture and 6th potency) and Ferrum Metallicum (30th potency)
selected as per similia principles were administered to 38 thalassemic patients receiving
Hydroxyurea (HU) therapy for a varying period of time. Levels of serum ferritin (SF), fetal
hemoglobin (HbF), hemoglobin (Hb), platelet count (PC), mean corpuscular volume (MCV),
mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH),
white blood cell (WBC) count, bilirubin content, alanine amino transferase (ALT), aspartate
amino transferase (AST) and serum total protein content of patients were determined before
and 3 months after administration of the homeopathic remedies in combination with HU to
evaluate additional benefits, if any, derived by the homeopathic remedies, by comparing the
data with those of 38 subjects receiving only HU therapy. Preliminary results indicated that
there was a significant decrease in the SF and increase in HbF levels in the combined, treated
subjects. Although the changes in other parameters were not so significant, there was a
significant decrease in size of spleen in most patients with spleenomegaly and improvement in
general health conditions along with an increased gap between transfusions in most patients
receiving the combined homeopathic treatment. The homeopathic remedies being inexpensive
and without any known side-effects seem to have great potentials in bringing additional benefits
to thalassemic patients; particularly in the developing world where blood transfusions suffer
from inadequate screening and fall short of the stringent safety standards followed in the
developed countries. Further independent studies are encouraged.
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Introduction
Thalassemia is a hereditary anemia resulting from defects
in hemoglobin production. It is among the most common
genetic disorders worldwide. About 4.83% of the world’s
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properly cited.population is carrying globin variants, including 1.67% of
the population that is heterozygous for a-thalassemia
and b-thalassemia (1). In b-thalassemic patients, there
is a decrease in the production of b-globin chains, as
a consequence of which multiple organs get affected (2) and
considerable mortality results. In HbE/b-thalassemia,
there is a mutation on both genes for the synthesis of
b-chain in adult and hemoglobin E meant for synthesis
of embryonic hemoglobin. Thalassemia is caused by any of
more than 200 point mutations and rarely by deletions (3).
It isclinically heterogeneous because various genetic lesions
variably impair globin chain synthesis. The anemia asso-
ciated with thalassemia may be moderate to severe
depending on the gene mutations involved. Severe anemia
is generally accompanied by ineffective erythropoiesis, with
bone expansion and extra medullary hematopoiesis in the
liver and spleen (also at other sites) generally resulting in
enlarged liver and spleen. Transfusion therapy is consid-
ered the main stay of treatment when the patients become
anemic beyond a threshold with all typical sufferings
of thalassemia, and treatment by the usual chelation
therapy is no more effective.
However, transfusion-related infections (primarily
Hepatitis B and C, or HIV) are now considered the major
cause of death in developing countries where proper blood
testing facility is not available. Although regular transfu-
sion therapy can help maintain growth and development
and also reduces hepato-spleenomegaly due to extra
medullary hematopoiesis, transfusion therapy is often
taken as the last resort in the developing countries, partly
for economic reasons and partly for lack of infra-structural
facilities. Therefore, iron chelation therapy occupies a
pivotal place in the control and management of thalasse-
mia, because this therapy is reported to double the life
expectancy of patients with thalassemia major (4,5).
Of the different chelators, Deferiprone, Deferoxamine,
etc., are regularly used, although they have been reported
to have considerable side effects and they are generally
more costly (6–10), precluding their use to a large extent
by poor patients. However, a number of new oral chelators
like Deferasirox (ICL 670) are presently under develop-
ment (11).
It is well established that affected patients do not become
anemic until the fetal (gamma) globin genes are devel-
opmentally silenced, and that patients with persistent high
levels of fetal globin typically have less severe anemia,
have milder clinical syndromes and are often transfusion
independent (12). Therefore, another approach through
augmenting the synthesis of fetal hemoglobin has been
made by using drugs like 5-Azacitidine, Hydroxyurea (HU)
and various butyrate derivatives (13). HU has shown
substantial benefits in a subgroup of patients with sickle
cell anemia (14) and in a few pediatric patients with
thalassemia where transfusion requirements were generally
eliminated after treatment with HU for 20 months
(15,16). However, several authors (13,17) reported the
role of HU in thalassemia therapy to be rather inconsistent,
some showing good responses while others did not (17,18).
Further, despite the beneficial effects of HU on erythropoi-
esis it may be difficult to correct the anemia associated with
thalassemia with the use of HU alone particularly in case
of genetic predisposition, such as the presence of Xmnl
polymorphism (19) and the type of thalassemia such as
hemoglobin E-thalassemia (20). Therefore, importance of
proper genetic screening has been emphasized by some
authors (21,22).
Recombinant human erythropoietin was employed to
achieve the benefit of increasing ‘thalassemic erythropoi-
esis’ without raising fetal hemoglobin in b-thalassemia
intermedia who had undergone spleenectomy (23).
Recently, the treatment with Darbepoetin-a was reported
to increase hemoglobin levels substantially in patients
with HbE/b-thalassemia disease. However, the search for
new compounds that augment fetal hemoglobin produc-
tion and are non-toxic in nature is still on in in vitro
system as well as on various animal models (24–26). Iron
overload causes most of the mortality and morbidity
associated with thalassemia, and serum ferritin (SF) is
most commonly measured as an indicator of iron stores.
Ferritin levels below 2500mg/ml are associated with
improved survival (1), and therefore drugs that are non-
toxic but capable of reducing SF level may be useful in
thalassemia.
In the present investigation, therefore, homeopathic
remedies that generally agreed with the symptoms of
thalassemic patients have been administered either singly
or in combination depending on changeable symptoms in
patients who have been on HU treatment for varying
periods of time from a few months to over 6 years. In
this investigation, the primary objectives were to exa-
mine if the homeopathic remedy, in combination with
HU, could bring beneficial effects, as manifested by
(i) diminishing SF level, (ii) augmenting HbF synthesis
and (iii) reduction of spleen size in patients with
spleenomegaly.
Material and Methods
Subjects
This research was conducted in compliance with the
protocols of Helsinki Declaration and the Institutional
Ethical Committee, University of Kalyani. Informed
consents were also obtained from the patients or their
parents (of minors), who volunteered to undertake this
study. Subjects were examined for their general health
and status of their spleen enlargement periodically.
Thirty-eight patients attending the Thalassemia Founda-
tion Clinic at F-44 Footnani Chamber, Corporation Place,
Kolkata-700013 from March 2001 to September 2006 had
been put on regular HU administration at rates varying
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depending on conditions of the patient. Most of these
patients were transfusion dependent.
Test protocols used and number of subjects for each
protocol
They were periodically examined for physical conditions
of liver and spleen and also for other blood parameters
like SF content, fetal hemoglobin (HbF) and hemoglobin
(Hb) content before and after administration of HU.
Tests were made on an actual cost-no-profit basis only
when patient’s condition demanded, as most of them
were extremely poor, many of them visiting from some
other districts like Midnapur, Cooch Behar in West
Bengal. The results and number of subjects who provided
samples for examination before and after HU treatment
totaled 38, of which 32 belonged to HbE/b type and
6 belonged to b-thalassemia major type. Of the 32 HbE/b
patients, the mean values of SF content of 18, and HbF
and Hb contents of all 32 were studied. Of the six
b-major patients, the mean values of SF content of four,
HbF level of three and Hb content of all six have been
obtained. This variation was unavoidable owing to
the disapproval of some patients for testing too many
blood parameters. Out of the 38 patients who received
homeopathic remedies as well as HU, 32 belonged to
HbE/b type and six to b-major type. Out of 32 patients
with HbE/b thalassemia, SF level was determined from
20 patients, HbF from 10, Platelet count (PC) from
27, Hb content from 27, mean corpuscular volume
(MCV), mean corpuscular hemoglobin concentration
(MCHC), and white blood cell (WBC) count from 27
patients each, bilirubin from 6, aspartate amino transfer-
ase (AST) from 4, alanine amino transferase (ALT) from
4, serum total protein content from 4 and mean
corpuscular hemoglobin (MCH) was analyzed from 27
patients.
Out of six b-major patients, SF and HbF level of four
subjects, PC and Hb content of six, MCV, MCHC and
WBC of six patients each, bilirubin, ALT, AST and
serum total protein from two subjects each and MCH
from six subjects were considered. Incidentally, the
patients showing symptoms of liver disorders and
jaundice were subjected to additional tests like AST,
ALT and bilirubin.
Age and sex of patients and blood transfusion periods
The age of these 38 patients ranged between 6 and
25 years, the majority being in 4–10 years’ age group. In
b-major group, there was one female and five male
subjects. In HbE/b group, there were 20 males and 12
females. Except for three patients, the remaining patients
had history of blood transfusion ranging from once in a
week to (rarely) once in 6 months.
Span of HU plus homeopathy treatment
The homeopathic treatment started from June 19, 2006 to
consecutive batches of patients who visited the clinic till
September 23, 2006; and the data of each patient under
homeopathic treatment for 3 months for various param-
eters of study were taken.
Urinary iron excretion
Initially, the first void urine of 20 patients of HbE/b group
was tested for iron contents in urine for 10 consecutive days
by method of atomic absorption spectrophotometry
(GBC Avanta, Australia) using authentic iron standards.
Homeopathic medicines, namely, Pulsatilla-30 (Puls-30),
Pulsatila mother tincture (Puls Q), Ferrum Metallicum-30
(Fer Met-30), and Ceanothus 6 (Cean-6) were administered
to three, five, three and six patients by following similia
principles. Three patients were given placebo. However,
their HU treatment was continued as well. The anemic
patients (or their parents) did not agree to give their blood
samples for 10 consecutive days for obvious reasons, but
agreed to give first void urine, for which the data of urinary
iron content of them (Fig. 1) could only be analyzed.
Source and Dose of Homeopathic Remedies
The homeopathic remedies were procured from HAPCO,
165, Bipin Behari Street, Kolkata. The mother tincture of
Ceanothus americanus is derived from alcoholic extract
of fresh leaves of New Jersey Tea (C. americanus Family:
Rhamnaceae) and that of Pulsatilla nigricans is derived
from the entire fresh plants (P. nigricans; Family:
Ranunculaceae) when in flowers (27). Ferrum metallicum
is derived from pure metallic iron by procedure of
homeopathic potentization (28).
Ten drops of the mother tincture of either Ceanothus
or Pulsatilla, prescribed as per simila principle of
homeopathy (i.e. taking into consideration guiding
symptoms in a holistic manner), were advised to be
taken with half cup water twice daily in empty stomach
for 3 weeks at a stretch and then withdrawal for a week.
The 30th potency (a serial homeopathic dilution of
1/10
60) of Pulsatilla and Ferrum Met and 6th potency
(a dilution of 1/10
12) of Ceanothus were used; five–six
drug soaked globules (No. 20) that formed a single dose,
were advised to be taken twice daily for 20 consecutive
days and then advised withdrawal for 10 days. The
remedies were cyclically repeated in this manner.
Methods
Five milliliters of blood was drawn from each patient by
venipuncture near the arm joint in glass vials containing
EDTA (anti-coagulant). Serum was extracted by centri-
fugation at 1000g and by collection of the supernatant.
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hemoglobin
Hemoglobin type HbF was quantified by automated
high-performance liquid chromatography (VARIANT;
Bio-Rad, Hercules, CA, USA) (29).
Immunoassay of Ferritin EIA
Enzyme immunoassay for the quantitative determination
of immunoglobulin subclass E (IgE) in human ferritin
was made in an ELISA Reader (Biorad, USA) by using
the kits from Genix Technology Inc, Canada).
For Hb analysis, a Cell Counter (Medonic CA 530, E.
Merck, Germany) was used by deploying standard kit
from E. Merck, Germany.
Total protein, ALT, AST and Bilirubin
These were recorded by Biochemical Semi auto-analyzer,
Microlab 300 (E. Merck, Germany).
Statistical Analysis
The levels of significance of differences were determined
between the data of parameters obtained before the
homeopathic drug administration and 3 months after
administration of the remedies by Student’s ‘t’ test
method.
Results
Urinary Iron Excretion Pattern
A careful analysis of the data (Fig. 1) revealed a relatively
low iron content from the first day and showed a wave
like curve in Cean-6-fed group. On the other hand,
the initial iron contents were recorded to be more in
the other drug-fed and placebo-fed series. There was also
a wave like fall and rise of iron contents in these groups
as well as in the placebo, except for the fact that the Puls-
30- and Puls-Q-fed group showed relatively more iron
excretion. Therefore, there was no clear indication of any
definite trend of iron excretion except for the fact that
iron excretion appeared to be marginally more in the
drug-fed groups (except Cean-6-fed group) and subse-
quently the three placebo-fed patients were also adminis-
tered homeopathic remedy as per similia principle. Since
the main objective was also to examine if the homeo-
pathic remedy could benefit the patients already on HU
treatment, we did not put any further importance to the
placebo-fed control as we considered the HU adminis-
tration group as our main control to evaluate additional
benefit, if any, derived by the administration of
homeopathic remedy.
Changes in SF, HbF and Hb Levels After Drug
Administration
There was a decrease of ferritin level and an increase of
HbF content in both HbE/b and b-major subjects after
administration of HU (Fig. 2A and B), although Hb
content in HbE/b group did not appreciably decrease.
There was a noticeable decrease in the Hb content of the
b-major group after administration of HU for a varying
period of time ranging from a therapy for 1–5 years
(complete data not shown). There was a significant
reduction of SF in the combined treatment (P<0.001) in
HbE/b group (Fig. 3A).
Although there was a further reduction in the b-major
group, the decrease was statistically insignificant like that
of only HU treatment group. There was also a significant
increase (P<0.05) in HbF level in HbE/b group but in the
b-major group there was actually a decrease in HbF level
(Fig. 3B). The Hb content in HbE/b group however, was
very marginally reduced, while there was a little increase in
Hb level in the b-major group (Fig. 3C).
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Figure 1. Iron contents of subjects fed with Placebo and Verum continuously for 10 days.
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The PC in both HbE/b and b-major were decreased
(Fig. 3D). The MCV of Hb E/b group remained more or
less the same, while there was a decrease in b-major group
(Fig. 3E), which was statistically insignificant. The MCHC
in HbE/b group remained more or less the same, while in
b-major there was a little increase (Fig. 3F). There was also
a little increase in MCH (Fig. 3G) of the b-major group;
however, the increase was statistically insignificant. The
WBC count in HbE/b was slightly increased while it was
marginally decreased in b-major (Fig. 3H). The bilirubin
content was same in HbE/b while it was decreased
marginally in b-major group (Fig. 3I). While there was a
distinct reduction in the AST (SGOT) level in Hb E/b
group, in b-major there was only a marginal increase noted,
thoughthelevelwas in the normal range (Fig.3J). The same
was true for ALT (SGPT) level (Fig. 3K), while in b-major
there was palpable change in serum total protein level,
there was marginal increase in serum total protein level
(Fig. 3L) of Hb E/b group.
Blood Transfusion Period
In most cases dependent on blood transfusion, there was an
increase in the period of their transfusion demand (ranging
between 25 and 75%) in the combined treatment group.
In two cases, patients used to have fever, before and after
transfusion, but after administration of homeopathic
remedies on similia principle for 3 months, the incidence
of fever disappeared.
Spleen Size and General Health
In the 30 patients having enlarged spleen of varying
lengths (total 125cm) before administration of homeo-
pathic remedy, there was a distinct reduction in length
(total 45cm); as many as 11 of them showed no palpable
enlarged spleen after homeopathic treatment. The general
health and spirits of the patients appeared to have
improved after this combined treatment in the majority
of the cases studied.
Discussion
In the present investigation, out of a total of 38 patients,
6 belonging to thalassemia major type (b-thalassemia)
and 32 to HbE/b type, the greater majority showed
positive response to combined homeopathic therapy.
There was a significant increase in induction of HbF in
them, which is very encouraging. In fact, augmentation of
fetal hemoglobin (HbF) synthesis is highly solicited in
thalassemic patients as high levels of fetal hemoglobin
production can ameliorate sickle cell disease and
b-thalassemia (30). Incidentally, oral administration of
HU alone has been reported to increase the level of HbF
in both thalassemia major and thalassemia intermedia
patients, with varying degree of response, presumably
because of the molecular heterogeneity of the b-globin
gene in major b-thalassemia and the complexity of
interacting genetic factors involved in HbF switching
in each respective patient (31). In fact, among the
various drugs recently proposed to improve the clinical
conditions in both sickle cell disease and b-thalassemia
(20,32–36), HU was stated to be the most effective. In
the present study, a noticeable increase in HbF was also
noted in patients receiving HU alone, but there was
further increase of HbF level in patients receiving the
combined homeopathic treatment, thereby showing addi-
tional beneficial effect of homeopathy. However, effect
on individual patients in regard to increase in HbF was
variable (data not shown) as also reported in the other
study (13). In case of Hb, in the only HU-treated
subjects, there was a considerable decrease of Hb content
in the b-major group, but there was actually a little
increase in the combined treated group. Therefore, on the
whole, there appeared to be additional benefit of homeo-
pathic drug in terms of both HbF and Hb contents.
It is suggested that HU produces fetal hemoglobin via
reactivation of gamma genes through some unknown
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134 Benefits of homeopathy on thalassemic patientsmolecular mechanism (37). These authors also reported
promising results of HU therapy in thalassemia
intermedia.
But there are reports in which some patients exhibited
insignificant or no change in HbF levels after HU
treatment (20,33). Nevertheless, HU therapy has been
termed as the most promising therapy because of the oral
route of administration, for being relatively inexpensive
and with no or little side effects (37). Therefore, if the
induction of HbF level could be further accelerated or
rejuvenated, as the homeopathic therapy appeared to
produce, could be of additional benefit to the patients.
The advantages of the homeopathic remedies are mani-
fold. They are also inexpensive, easily available, taken in
micro doses and without any known side-effects.
How the homeopathic remedies could bring forth such
positive changes remains unclear. But the present results
would also lend support to the contention (38–40) that
the potentized homeopathic remedies possibly acted
through regulation of specific and relevant gene expres-
sion responsible for the apparently enhanced synthesis of
the HbF and decrease of ferritin level. While in the
advanced countries the treatment and management
strategies have made significant progress in the reduction
of thalassemia to a great extent, such treatment strategies
are beyond reach of the poor patients inhabiting
developing countries. Incidentally, homeopathic remedies
also showed considerable potentials to ameliorate arseni-
cosis (41–43), a burning public health problem of arsenic
exposure through groundwater contamination in some
third world countries, because only limited success could
so far be achieved with the orthodox medicine tested to
cure arsenicosis. Therefore, the initial results of the
present study are very encouraging and need further trial
by other researchers independently to verify and confirm
(or refute) our findings. Further works involving addi-
tional important parameters are presently in progress.
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